Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepsivac for Hospitalized Non-Critically Ill COVID-19 Patients
NCT04358809Phase 3Unknown
- Sponsor
- Cadila Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MYCIDAC-C in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cadila Pharmaceuticals. Primary endpoint: Number of patients with increased disease severity at 28 days. Status: unknown.
02
Drugs
MYCIDAC-C
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04358809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358809.